Stock Analiz

Vir Biotechnology, Inc. (VIR) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Vir Biotechnology’s revenue went from $3M in fiscal 2017 to $69M in fiscal 2025, growth of about 49.8% a year.

Net income in fiscal 2025 was -$438M, a net margin of -638.9%; the best year in this period was 2021 with $529M.

Over the twelve months to September 30, 2026, revenue was $303M and net income -$185M.

Free cash flow was -$397M in fiscal 2025 and positive in 1 of the 9 years shown.

The diluted share count rose 6336% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $3M172018: $11M182019: $8M192020: $76M202021: $1.1B212022: $1.6B222023: $86M232024: $74M242025: $69M25$69M
Net income
2017: -$70M172018: -$116M182019: -$175M192020: -$299M202021: $529M212022: $516M222023: -$615M232024: -$522M242025: -$438M25-$438M
Free cash flow
2017: -$69M172018: -$102M182019: -$139M192020: -$197M202021: -$69M212022: $1.6B222023: -$800M232024: -$454M242025: -$397M25-$397M
EPS (diluted)
2017: $-32.45172018: $-15.12182019: $-5.76192020: $-2.51202021: $3.96212022: $3.83222023: $-4.59232024: $-3.83242025: $-3.1625$-3.16

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$303M$69M$74M$86M$1.6B$1.1B$76M$8M$11M$3M
Gross profit—$69M$73M$83M$1.5B$1.0B$76M$8M——
Operating income-$211M-$479M-$587M-$684M$833M$421M-$297M-$178M-$119M-$81M
Net income-$185M-$438M-$522M-$615M$516M$529M-$299M-$175M-$116M-$70M
EPS (diluted)$-1.18$-3.16$-3.83$-4.59$3.83$3.96$-2.51$-5.76$-15.12$-32.45
R&D$413M$456M$506M$580M$475M$448M$302M$148M$100M$63M
Revenue growth—−7.6%−13.9%−94.7%+47.5%+1334.4%+843.9%−24.2%+293.9%—

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow-$141M-$392M-$446M-$779M$1.7B-$48M-$191M-$130M-$94M-$66M
Capital spending-$804000-$5M-$7M-$22M-$68M-$22M-$7M-$9M-$8M-$3M
Free cash flow-$142M-$397M-$454M-$800M$1.6B-$69M-$197M-$139M-$102M-$69M
Dividends paid—$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$46M$49M$78M$111M$102M$84M$28M$9M$5M$5M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$461M$901M$1.5B$2.4B$565M$737M$383M$98M$188M
Debt—$98M$98M$125M$128M$137M$70M$0$0—
Equity—$765M$1.2B$1.6B$2.1B$1.4B$717M$424M-$179M-$69M
Total assets—$1.0B$1.4B$1.9B$2.8B$2.0B$919M$512M$192M—
Shares (diluted)169M139M136M134M135M133M119M30M8M2M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin—100.0%98.9%96.8%90.9%94.0%100.0%100.0%——
Operating margin-69.8%-699.2%-791.3%-794.0%51.6%38.4%-388.9%-2199.7%-1112.6%-3009.5%
Net margin-61.0%-638.9%-703.4%-713.7%31.9%48.2%-391.1%-2159.0%-1086.3%-2579.5%
FCF margin-46.8%-578.5%-611.4%-928.7%98.7%-6.3%-258.6%-1712.7%-958.8%-2552.6%
ROIC—-43.9%-46.9%-39.1%25.8%25.8%-29.8%-33.2%——
ROE—-57.2%-45.4%-38.7%24.8%36.9%-41.7%-41.2%64.7%101.4%

Frequently asked questions

What is Vir Biotechnology’s annual revenue?

$69M in fiscal 2025 and $303M over the twelve months to September 30, 2026.

How much profit does Vir Biotechnology make?

Net income was -$438M in fiscal 2025 (net margin -638.9%).

Is Vir Biotechnology’s revenue growing?

No: revenue fell 7.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.